{"entity":{"id":"nct06699836","kind":"trial","name":"CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen","aka":[],"tldr":"A phase 2 trial of Pembrolizumab in colorectal cancer, run by CytoDyn, Inc., active and no longer recruiting.","summary":"CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen is a phase 2 interventional study registered as NCT06699836 by CytoDyn, Inc., with 66 participants enrolled, started 2025-06-16 and due to reach its primary completion in 2028-01. Interventions recorded: 350 mg leronlimab, 700 mg leronlimab, 200 mg pembrolizumab. Conditions listed: Metastatic Colorectal Cancer (mCRC). No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06699836","url":"https://clinicaltrials.gov/study/NCT06699836"}],"tags":["ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06699836","phase":"2","setting":"A Phase Two Study Evaluating Two Doses of Leronlimab (PRO 140) In Combination With Trifluridine + Tipiracil (TAS-102) + Bevacizumab in Participants With Microsatellite Stable (MSS), Relapsed Refractory Metastatic Colorectal Cancer (mCRC)","sponsor":"CytoDyn, Inc.","enrolled":66,"outcomes":[]},"route":"/trials/nct06699836/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}]}}